2018 Investor Presentation

Trulieve Reports Third Quarter 2022 Results and Drives Forward Progress on Strategic Vision

November 9, 2022 at 4:15 PM EST
  • Revenue increased 34% year over year to $301 million with GAAP gross margin of 56%
  • Industry leading U.S. retail network of 176 dispensaries, supported by over 4 million square feet of cultivation and processing capacity
  • Capital, data, distribution and scaled capacity position Trulieve for Cannabis 2.0

TALLAHASSEE, Fla., Nov. 9, 2022 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced its results for the quarter ended September 30, 2022. Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles unless otherwise indicated. Numbers may not sum perfectly due to rounding.  

Q3 2022 Financial and Operational Highlights*

  • Grew revenue by 34% year over year to $301 million, with 94% of revenue from retail sales.
  • Achieved GAAP gross margin of 56%, with gross profit of $168 million.
  • Reported net loss of $115 million. Adjusted net income of $4 million* excludes $26 million of transaction, acquisition, integration, and other non-recurring charges; $93 million in asset impairments, disposals and discontinued operations, primarily associated with the strategic repositioning away from margin dilutive and cash flow negative assets through the closure of dispensaries in California, redundant cultivation in Florida and the exit of wholesale operations in Nevada.
  • Generated adjusted EBITDA of $99 million*, or 33% margin.
  • Ended the third quarter with $114 million in cash.
  • Invested $38 million in capital expenditures. Expect significant decline in supply chain investments in 2023 following a multi-year investment cycle to support future growth.
  • Coordinated response efforts for Hurricane Ian. Deployed mobile tech and operational teams to deliver supplies and donations, assist recovery efforts, and restore operations.
  • Expanded market leading retail positions in Arizona, Florida, and West Virginia, with 11 new dispensary openings, including the first Trulieve branded store in Arizona, in the Roosevelt Row neighborhood of Phoenix.
  • Increased utilization at new indoor 750K square foot cultivation facility in Florida, allowing for lower production costs and banking of legacy capacity for future use.
  • Commenced cultivation operations in Georgia to support production of low THC oil products for retail launch in early 2023.
  • Rolled out customer data platform in Arizona and Pennsylvania while deepening capabilities in Florida. Continue to refine our digital customer journey using AI driven technology and integrated commerce capabilities.
  • Contributed to the Smart and Safe Florida campaign, which aims to legalize adult use marijuana in Florida through a ballot initiative in November 2024.

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

Recent Developments

  • Launched Khalifa Kush Cannabis products exclusively in Florida at Trulieve dispensaries in October.
  • Expanded retail network in core markets with two new dispensaries in Arizona and Florida.
  • Rebranded Glendale, Arizona dispensary. Plan to rebrand additional Arizona locations ahead of peak tourism and sporting events in February and March 2023.
  • Awarded cannabis cultivation license in Connecticut which allows for two additional dispensaries.
  • Currently operate 178 retail dispensaries and over 4 million square feet of cultivation and processing capacity in the United States.

Management Commentary
"Our team demonstrated tremendous flexibility and cross functional capabilities during the third quarter," said Kim Rivers, Trulieve CEO. "We navigated macroeconomic pressure, changes to dosing limits in our core state of Florida, and the impact of Hurricane Ian while making further progress streamlining the organization."   

Rivers continued, "U.S. cannabis has significant white space ahead, with many states yet to implement medical or adult use programs and a growing appetite for substantive federal reform. Trulieve has been preparing for this next phase of industry evolution for years, building our regional hub strategy, scaling cutting edge cultivation and manufacturing capacity, expanding our leading retail platform, investing in data technology and perfecting the customer journey."

Outlook
We anticipate fourth quarter results will be influenced by holiday retail performance and promotional activity across core markets during the latter half of the quarter. Based on our performance year to date and current trends, we are targeting the low end of 2022 guidance of $1.25 billion to $1.3 billion in revenue and $415 million to $450 million in Adjusted EBITDA.

Financial Highlights*

Results of Operations

For the Three Months Ended

For the Nine Months Ended





(Figures in millions and %
change based on these
figures)

September
30, 2022

September
30, 2021

change

June 30,
2022

change

September
30, 2022

September
30, 2021

change





Revenue

$

301

$

224

34 %

$

319

-6 %

$

938

$

633

48 %



Gross Profit

$

168

$

154

9 %

$

184

-9 %

$

532

$

434

23 %



Gross Margin %


56 %


69 %



58 %



57 %


69 %




Adjusted Gross Profit

$

172

$

155

11 %

$

184

-6 %

$

541

$

441

23 %



Adjusted Gross Margin %


57 %


69 %



58 %



58 %


70 %




Operating Expenses

$

196

$

88

123 %

$

143

37 %

$

488

$

219

123 %



Operating Expenses %


65 %


39 %



45 %



52 %


35 %




Net Income (Loss)**

$

(115)

$

19

---

$

(22)

---

$

(169)

$

90

---



Net Income (Loss) Continuing Ops

$

(77)

$

19

---

$

(22)

---

$

(129)

$

90

---



Adjusted Net Income (Loss)

$

4

$

36

-90 %

$

(1)

---

$

5

$

122

---



Diluted Shares Outstanding


189


137



187



188


131




EPS Continuing Ops

$

(0.41)

$

0.14

---

$

(0.11)

---

$

(0.68)

$

0.68

---



Adjusted EPS

$

0.02

$

0.26

-92 %

$

0.00

---

$

0.03

$

0.91

---



Adjusted EBITDA

$

99

$

98

1 %

$

111

-11 %

$

315

$

284

11 %



Adjusted EBITDA Margin %


33 %


44 %



35 %



34 %


45 %




*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

**Includes discontinued operations.

Conference Call
The Company will host a conference call and live audio webcast on November 9, 2022, at 5:30 P.M. Eastern time, to discuss its third quarter 2022 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.

North American toll free: 1-888-254-3590
International: 1-786-789-4797                              

A live audio webcast of the conference call will be available at:
https://app.webinar.net/xX6Q5JE71z3

A powerpoint presentation and archived replay of the webcast will be available at
https://investors.trulieve.com/events-presentations

The Company's Form 10-Q for the quarter ended September 30, 2022, will be available on the SEC's website or at https://investors.trulieve.com/financial-information/quarterly-results. The Company's Management Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company's profile on SEDAR and on its website at https://investors.trulieve.com/financial-information/quarterly-results. This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.

 

Trulieve Cannabis Corp.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except per share data)




September 30,
2022



December 31,
2021


ASSETS







Current assets:







Cash and cash equivalents


$

114,468



$

230,085


Restricted cash






3,013


Accounts receivable, net



11,309




8,563


Inventories, net



301,239




209,943


Notes receivable - current portion



715




1,530


Prepaid expenses and other current assets



62,068




68,145


Assets associated with discontinued operations



2,838




3,615


Total current assets



492,637




524,894


Property and equipment, net



795,506




779,413


Right of use assets - operating, net



100,864




111,723


Right of use assets - finance, net



75,305




66,764


Intangible assets, net



1,027,058




1,081,240


Goodwill



791,495




765,358


Notes receivable, net



12,059




12,147


Other assets



21,531




17,640


Long-term assets associated with discontinued operations



4,503




52,167


TOTAL ASSETS


$

3,320,958



$

3,411,346


LIABILITIES







Current liabilities:







Accounts payable and accrued liabilities



87,773




93,801


Income tax payable



4,681




28,084


Deferred revenue



6,385




7,168


Notes payable - current portion, net



4,823




10,052


Operating lease liabilities - current portion



10,779




10,020


Finance lease liabilities - current portion



8,719




6,185


Construction finance liabilities - current portion



1,137




991


Contingencies



25,590




13,017


Liabilities associated with discontinued operations



390




92


Total current liabilities



150,277




169,410


Long-term liabilities:







Notes payable



7,942




6,456


Private placement notes, net



540,301




462,929


Warrant liabilities



268




2,895


Operating lease liabilities



110,625




107,570


Finance lease liabilities



75,011




65,244


Construction finance liabilities



182,257




175,198


Deferred tax liabilities



220,206




241,882


Other long-term liabilities



8,616




8,400


Long-term liabilities associated with discontinued operations



14,575




23,989


TOTAL LIABILITIES



1,310,078




1,263,973


Commitments and contingencies (see Note 22)







SHAREHOLDERS' EQUITY







Common stock, no par value; unlimited shares authorized. 185,880,209 issued and outstanding as of September 30, 2022 and 180,504,172 issued and outstanding as of December 31, 2021.







Additional paid-in-capital



2,041,748




2,008,100


Accumulated (deficit) earnings



(31,299)




137,721


Non-controlling interest



431




1,552


TOTAL SHAREHOLDERS' EQUITY



2,010,880




2,147,373


TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY


$

3,320,958



$

3,411,346


 

Trulieve Cannabis Corp.
Condensed Consolidated Statements of Operations and
Comprehensive (Loss) Income (Unaudited)
(in thousands, except per share data)




Three Months Ended



Nine Months Ended




September 30,
2022



September 30,
2021



September 30,
2022



September 30,
2021


Revenues, net of discounts


$

300,793



$

224,092



$

937,612



$

633,037


Cost of goods sold



132,760




70,147




405,278




199,345


   Gross profit



168,033




153,945




532,334




433,692


Expenses:













Sales and marketing



75,915




51,724




224,026




142,858


General and administrative



37,646




28,223




104,840




55,874


Depreciation and amortization



30,190




7,728




88,645




19,829


Impairment and disposal of long-lived assets, net



52,035




(5)




70,151




(5)


Total expenses



195,786




87,670




487,662




218,556


  (Loss) Income from operations



(27,753)




66,275




44,672




215,136


Other income (expense):













Interest expense, net



(19,264)




(6,145)




(56,815)




(20,693)


Change in fair value of derivative liabilities - warrants



365







2,627





Impairment and disposal of non-operating assets, net



(2,604)







(6,004)





Other income (expense), net



448




89




3,016




385


Total other expense



(21,055)




(6,056)




(57,176)




(20,308)


  (Loss) Income before provision for income taxes



(48,808)




60,219




(12,504)




194,828


Provision for income taxes



28,199




41,603




116,742




105,254


   Net (loss) income from continuing operations and comprehensive (loss) income



(77,007)




18,616




(129,246)




89,574


   Net loss from discontinued operations, net of tax benefit of $12,981, $-, $14,439, and $-, respectively



(38,065)







(42,329)





Net (loss) income



(115,072)




18,616




(171,575)




89,574


   Less: Net loss and comprehensive loss attributable to non-controlling interest from continuing operations



(518)







(2,555)





   Net (loss) income and comprehensive (loss) income attributable to common shareholders


$

(114,554)



$

18,616



$

(169,020)



$

89,574















Net (loss) income per share - Continuing operations:













Basic


$

(0.41)



$

0.15



$

(0.68)



$

0.73


Diluted


$

(0.41)



$

0.14



$

(0.68)



$

0.68


Net loss per share - Discontinued operations:













Basic and diluted


$

(0.20)






$

(0.23)





Weighted average number of common shares used in computing net (loss) income per share:













Basic



188,597,094




128,146,298




187,549,359




122,983,729


Diluted



188,597,094




136,909,266




187,549,359




130,927,083


Non-GAAP Financial Measures
In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including adjusted EBITDA, adjusted gross profit, adjusted net income (loss), adjusted net income (loss) per diluted share. Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.

Reconciliation of Non-GAAP Adjusted EBITDA
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP Adjusted EBITDA, for each of the periods presented: 

(Amounts expressed in millions of United
States dollars)

For the Three Months Ended

For the Nine Months Ended





September 30,
2022

September 30,
2021

June 30, 2022

September 30,
2022

September 30,
2021





Net Income (Loss) GAAP

$

(114.6)

$

18.6

$

(22.5)

$

(169.0)

$

89.6



Add (Deduct) Impact of:













Interest Expense, net

$

19.3

$

6.1

$

19.7

$

56.8

$

20.7



Provision For Income Taxes

$

28.2

$

41.6

$

45.4

$

116.7

$

105.3



Depreciation and Amortization

$

30.2

$

7.7

$

30.0

$

88.6

$

19.8



Depreciation in COGS

$

14.6

$

5.7

$

13.8

$

39.1

$

14.4



EBITDA

$

(22.3)

$

79.8

$

86.4

$

132.3

$

249.7






Impairment and Disposal of Long-lived Assets, net

$

52.0

$

0.0

$

4.3

$

70.2

$

0.0



Results of Discontinued Operations

$

38.1

$

0.0

$

1.9

$

42.3

$

0.0



Acquisition and Transaction Costs

$

7.0

$

11.1

$

7.0

$

17.2

$

14.3



Integration and Transition Costs

$

6.7

$

0.8

$

5.1

$

17.1

$

2.7



Other Non-Recurring Costs

$

1.9

$

0.2

$

3.5

$

11.6

$

1.6



Share-Based Compensation and Related Premiums

$

4.3

$

4.9

$

5.7

$

14.6

$

6.4



Legislative Campaign Contributions

$

10.0

$

0.0

$

0.0

$

10.0

$

0.0



Impairment and Disposal of Non-Operating Assets, net

$

2.6

$

0.0

$

0.7

$

6.0

$

0.0



Inventory Step Up Fair Value

$

0.0

$

0.7

$

0.6

$

1.0

$

3.2



Covid Related Expenses

$

0.2

$

0.5

$

0.2

$

0.8

$

6.0



Other Expense (Income), net

$

(0.4)

$

(0.1)

$

(1.7)

$

(3.0)

$

(0.4)



Fair Value of Derivative Liabilities - Warrants

$

(0.4)

$

0.0

$

(1.4)

$

(2.6)

$

0.0



Results of Entities Not Legally Controlled

$

(0.9)

$

0.0

$

(1.1)

$

(1.9)

$

0.0



Adjusted EBITDA Non-GAAP

$

98.8

$

98.0

$

111.3

$

315.5

$

283.7



Reconciliation of Non-GAAP Adjusted Gross Profit
The following table presents a reconciliation of GAAP gross profit to non-GAAP adjusted gross profit, for each of the periods presented:

(Amounts expressed in millions of
United States dollars)

For the Three Months Ended

For the Nine Months Ended





September 30,
2022

September 30,
2021

June 30,
2022

September 30,
2022

September 30,
2021





Gross Profit GAAP

$

168.0

$

153.9

$

183.8

$

532.3

$

433.7



Gross Margin % GAAP


56 %


69 %


58 %


57 %


69 %



Add (Deduct) Impact of:



Inventory Step Up Fair Value

$

0.0

$

0.7

$

0.6

$

1.0

$

3.2



Transaction, Acquisition, and Integration Costs

$

3.8

$

0.4

$

(0.8)

$

7.4

$

3.9



Adjusted Gross Profit Non-GAAP

$

171.9

$

155.0

$

183.7

$

540.8

$

440.8



Adjusted Gross Margin % Non-GAAP


57 %


69 %


58 %


58 %


70 %



Reconciliation of Non-GAAP Adjusted Net Income
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP adjusted net income, for each of the periods presented: 

(Amounts expressed in millions of United States dollars)

For the Three Months Ended

For the Nine Months Ended






September 30,
2022

September 30,
2021

June 30,
2022

September 30,
2022

September 30,
2021







Net Income (Loss) GAAP

$

(114.6)

$

18.6

$

(22.5)

$

(169.0)

$

89.6



Add (Deduct) Impact of:




Share-Based Compensation Related Premiums

$

0.0

$

4.2

$

0.0

$

0.0

$

4.2



Fair Value of Derivative Liabilities - Warrants

$

(0.4)

$

0.0

$

(1.4)

$

(2.6)

$

0.0



Inventory Step Up Fair Value

$

0.0

$

0.7

$

0.6

$

1.0

$

3.2



Transaction, Acquisition, and Integration Costs

$

25.5

$

12.2

$

15.6

$

55.9

$

18.7



Covid Related Expenses

$

0.2

$

0.5

$

0.2

$

0.8

$

6.0



Impairment and Disposal of Non-Operating Assets, net

$

2.6

$

0.0

$

0.7

$

6.0

$

0.0



Impairment and Disposal of Long-lived Assets, net

$

52.0

$

0.0

$

4.3

$

70.2

$

0.0



Results of Discontinued Operations


38.1

$

0.0

$

1.9

$

42.3

$

0.0



Adjusted Net Income (Loss) Non-GAAP

$

3.5

$

36.2

$

(0.6)

$

4.6

$

121.7



Reconciliation of Non-GAAP Adjusted Earnings Per Share
The following table presents a reconciliation of GAAP earnings (loss) per share to non-GAAP adjusted earnings per share, for each of the periods presented:

(Amounts expressed in millions of United
States dollars)

For the Three Months Ended

For the Nine Months Ended





September 30,
2022

September 30,
2021

June 30, 2022

September 30,
2022

September 30,
2021





Earnings (Loss) Per Share GAAP

$

(0.61)

$

0.14

$

(0.12)

$

(0.90)

$

0.68



Add (Deduct) Impact of:



Share-Based Compensation Related Premiums

$

0.00

$

0.03

$

0.00

$

0.00

$

0.03



Fair Value of Derivative Liabilities - Warrants

$

(0.00)

$

0.00

$

(0.01)

$

(0.01)

$

0.00



Inventory Step Up Fair Value

$

0.00

$

0.01

$

0.00

$

0.01

$

0.02



Transaction, Acquisition, and Integration Costs

$

0.14

$

0.09

$

0.08

$

0.30

$

0.14



Covid Related Expenses

$

0.00

$

0.00

$

0.00

$

0.00

$

0.05



Impairment and Disposal of Non-Operating Assets, net

$

0.01

$

0.00

$

0.00

$

0.03

$

0.00



Impairment and Disposal of Long-lived Assets, net

$

0.28

$

0.00

$

0.02

$

0.37

$

0.00



Results of Discontinued Operations

$

0.20

$

0.00

$

0.01

$

0.23

$

0.00



Adjusted Earnings Per Share Non-GAAP

$

0.02

$

0.27

$

0.00

$

0.03

$

0.93



Forward-Looking Statements
This news release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements relate to the Company's expectations or forecasts of business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding the Company's expected revenue and adjusted EBITDA for fiscal 2022, its plans for streamlining operations and navigating short term headwinds, and its beliefs as to its positioning for cannabis 2.0. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risks discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and in our periodic reports subsequently filed with the United Sates Securities and Exchange Commission and in the Company's filings on SEDAR at www.sedar.com. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.

Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve  

Investor Contact
Christine Hersey, Executive Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Rob Kremer, Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-reports-third-quarter-2022-results-and-drives-forward-progress-on-strategic-vision-301673577.html

SOURCE Trulieve Cannabis Corp.